BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics

Monday, April 13, 2026 · research and markets

AI Briefing

BRAF-mutated NSCLC market growth driven by increasing incidence rate and unmet treatment needs.
Limited approved therapies, with Tafinlar and Mekinist combo as the only option.
Emerging therapies from key players like Novartis, Genentech, and C4 Therapeutics offer new treatment options.